The NLRP3 inflammasome in burns: a novel potential therapeutic target

Haihong Li1, Junhong Zhao2, Leilei Cao1

  • 1Department of Burns and Plastic Surgery, Seventh Affiliated Hospital, Sun Yat-sen University, 628 Zhenyuan Road, Guangming District, Shenzhen 518107, Guangdong Province, China.

Burns & Trauma
|July 3, 2024
PubMed

Insights

Burns cause significant public health issues. This review explores how the NLRP3 inflammasome impacts burn healing and discusses NLRP3 inhibitors as potential therapeutic targets for improved burn wound treatment.

Area of Science:

  • Biomedical science
  • Wound healing research
  • Inflammation and immunology

Background:

  • Burns represent a substantial public health burden with significant physical, psychological, and economic impacts.
  • Despite advances, burn wounds often exhibit delayed healing or severe complications.
  • The nucleotide-binding oligomerization domain-like receptors (NLRs) family pyrin domain-containing 3 (NLRP3) inflammasome is a key regulator in wound repair.

Purpose of the Study:

  • To review the current understanding of NLRP3 inflammasome roles in burn wound healing.
  • To summarize the regulatory mechanisms of NLRP3 inflammasome in burn pathophysiology.
  • To highlight preclinical findings on NLRP3 inhibitors for burn treatment.

Main Methods:

  • Literature review of current scientific understanding.
  • Analysis of pathophysiological mechanisms in burn wound healing.
  • Examination of preclinical studies involving NLRP3 inhibitors.

Main Results:

  • The NLRP3 inflammasome plays a critical role in regulating burn wound healing processes.
  • Understanding NLRP3 mechanisms can identify targets for promoting healing and reducing complications.
  • Preclinical studies suggest NLRP3 inhibitors hold therapeutic potential for burn wounds.

Conclusions:

  • NLRP3 inflammasome modulation is a promising therapeutic strategy for burn wound management.
  • Targeting NLRP3 could improve healing outcomes and restore skin structure and function.
  • Further research into NLRP3-targeted therapies is warranted for clinical application.